Skip Nav Destination
Tagraxofusp, a CD123-targeted therapy, for chronic myelomonocytic leukemia: final results of a phase 1/2 study
A phase 1 study of IO-202, an anti-LILRB4 antibody, in chronic myelomonocytic leukemia and acute myeloid leukemia
Issue Archive
November 2025
In Progress
Volume 2 Issue 4 | Blood Neoplasia | American Society of Hematology
BASIC MECHANISMS OF NEOPLASIA
CLINICAL TRIALS AND OBSERVATIONS
Tagraxofusp, a CD123-targeted therapy, for chronic myelomonocytic leukemia: final results of a phase 1/2 study
Clinical Trials & Observations
Mrinal M. Patnaik,Haris Ali,Eunice S. Wang,Abdulraheem Yacoub,James M. Foran,Vikas Gupta,Gary J. Schiller,Don Ambrose Stevens,Moshe Talpaz,Sarah Wall,Terra L. Lasho,Abhishek A. Mangaonkar,Talha Badar,Ross Lindsay,Antonio Galleu,Ira Gupta,Naveen Pemmaraju,Guillermo Garcia-Manero
A phase 1 study of IO-202, an anti-LILRB4 antibody, in chronic myelomonocytic leukemia and acute myeloid leukemia
Clinical Trials & Observations
Ahmed Aribi,Gabriel N. Mannis,Yazan F. Madanat,Brian A. Jonas,Neil Dunavin,Gail J. Roboz,Deepa Jeyakumar,Guillermo Garcia-Manero,Hongtao Liu,Hetty E. Carraway,Jennifer N. Saultz,William Blum,Gary Schiller,Tao Huang,Paul Woodard,Barbara Klencke,X. Charlene Liao,Hong Xiang,Daniel A. Pollyea,Courtney D. DiNardo
MYELOID NEOPLASIA
V-FAST: a phase 1b master trial to investigate CPX-351 combined with targeted agents in adults with newly diagnosed AML
Vinod A. Pullarkat,Mark Levis,James McCloskey,Gabriel N. Mannis,Stephen A. Strickland,Amir T. Fathi,Tara L. Lin,Vijaya R. Bhatt,Thuva Vanniyasingam,Divya Chakravarthy,Yana Lutska,Stefan Faderl,Ronald S. Cheung,Harry P. Erba
Intensive chemotherapy vs venetoclax/hypomethylating agents for patients aged 60 to 75 years with favorable, NPM1-mutated AML
Andrew D Zale,Venkata Preetam Sandeep Kaduluri,Jonathan A Webster,Mark J Levis,Ivana Gojo,Amy E DeZern,Gabriel Ghiaur,Lukasz P Gondek,William Brian Dalton,Theodoros Karantanos,Tania Jain,Gabrielle T Prince,Richard J Jones,B. Douglas Smith,Alexander J Ambinder
Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1
Courtney D. DiNardo,Wei-Ying Jen,Guillermo Montalban-Bravo,Xuemei Wang,Sanam Loghavi,Sravanthi Lavu,Nicholas J. Short,Kelly Chien,Ghayas C. Issa,Naveen Pemmaraju,Musa Yilmaz,Michael Andreeff,Gautam Borthakur,Tapan M. Kadia,Naval G. Daver,Guillermo Garcia-Manero,Christopher P. Mill,Xiaoping Su,Warren Fiskus,Kapil N. Bhalla
REVIEW ARTICLE
RESEARCH LETTER
Eμ-TCL1 mice with conditional human BCL2 knockin as novel B-cell lymphoma model for studying venetoclax effects in vivo
Ismini Halmer,Daniela Asslaber,Laura Beckmann,Gero Knittel,Hans Christian Reinhardt,Hamid Kashkar,Michael Hallek,Jens Löber,Björn Chapuy,Alexander Egle,Günter Krause,Alexandra da Palma Guerreiro,Lukas P. Frenzel
A prospective study of prophylactic dexamethasone with glofitamab in relapsed/refractory large B-cell lymphoma
J. Erika Haydu,Matthew M. Lei,Robert A. Redd,Jeffrey A. Barnes,Elijah P. Darnell,Ephraim P. Hochberg,P. Connor Johnson,Ronald W. Takvorian,James I. Weitzman,Elliot C. Woods,Tiffany L. Hurvitz,Courtney D. Lafranchi,Patricia Livingstone,Julia M. Lynch,Emily N. Patterson,Jack E. Malespini,Brianne M. McGree,Alexa O. Santilli,Katherine A. Thorp,Maryanne M. Sherburne,Lindsey B. Wardrop,Uvette Y. Lou,Mark N. Sorial,Catherine Cho,Josie Ford,Ronnie Nemac,Jacob D. Soumerai,Jeremy S. Abramson
Lymphoid Neoplasia
Shelter in place: live CLL cells inside the bone marrow fibroblasts and its implication in residual disease persistence
Pin Lu,Carrie A Franzen,Aldana Vistarop,Andrey Efimov,SK Abrar Shahriyar,Shengchun Wang,Shilpa Rao,Marcus Messmer,Shazia Nakhoda,Edna Cukierman,Shuo Ma,Janusz Franco-Barraza,Juehua Gao,Y. Lynn Wang
Advertisement intended for health care professionals
Advertisement intended for health care professionals